Gibson Dunn Advises LifeSci Capital in Quince Therapeutics’ Acquisition of Orphai Therapeutics

Gibson Dunn has advised LifeSci Capital in its role as financial advisor for Quince Therapeutics, Inc. during the acquisition of Orphai Therapeutics Inc., which included a concurrent private placement financing. This strategic acquisition aims to enhance Quince Therapeutics’ capabilities in the life sciences sector. The transaction was facilitated by partners Ryan Murr and Branden Berns, leveraging their expertise in mergers and acquisitions.